Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.39 |
| ▸ | NPY1R | P25929 | 10/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.39 |
| ▸ | NPY2R | P49146 | 6/20 | 0.39 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | TFPI | P10646 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997472 | 0.97 | QRFPR (0.41) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL29875551 | 0.90 | C3AR1 (0.40) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL31006052 | 0.90 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL30862191 | 0.90 | TFPI (0.42) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29564351 | 0.89 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL26887003 | 0.88 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30481170 | 0.87 | NOD1 (0.43) | QRFPRSIRT6SIRT1 | |
| SCHEMBL30481161 | 0.87 | NOD1 (0.43) | QRFPRSIRT6SIRT1 | |
| SCHEMBL29565556 | 0.87 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL29630598 | 0.87 | QRFPR (0.42) | NPY4RNPY1RNPY5RNPY2RQRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | NPY4R 3170/4885NPY1R 3454/4885NPY5R 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.